Account
Poster
02.03.2026
Private versus public access: Exploring how obesit...

Obesity medicines (OMs), including GLP-1 receptor agonists such as semaglutide (Wegovy®) and tirzep...

Read more
Poster
15.10.2025
What Are the Likely PICOs for Tovorafenib and Lifi...

Objectives:  ​​EUHTA regulation has applied from the 1st January 2025 for oncology pr...

Read more
Poster
15.10.2025
How the EU JCA could interface with Regional Prici...

Objectives: ​​To analyse how the mandatory EU Joint Clinical Assessment (JCA) could in...

Read more
Poster
15.10.2025
Building the bridge to access: Leveraging RWE from...

Objectives:  ​​Early-access schemes enable patients to access promising therapies—particularl...

Read more
Poster
15.10.2025
Budget impact minimisation approaches used across ...

Objectives: The market entry of effective obesity medications offers promise to patients with obesit...

Read more
Poster
15.10.2025
Revisiting rarity: Would yesterday’s NICE highly...

Objectives:  ​​In March 2025, NICE adopted new HST routing criteria for evaluating technolo...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch